These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15193200)

  • 1. Availability of hormone replacement therapy products in Canada.
    Brown TE; Lalonde AB; Fortin C; Lea R; Azzarello D
    J Obstet Gynaecol Can; 2004 Jun; 26(6):560-3. PubMed ID: 15193200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.
    Rawson NS
    Can J Clin Pharmacol; 2002; 9(2):73-8. PubMed ID: 12172587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.
    Pieterson EA
    J Clin Pharmacol; 1992 Oct; 32(10):889-96. PubMed ID: 1447395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
    Rawson NS
    Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian access to hormonal contraceptive drug choices.
    Azzarello D; Collins J
    J Obstet Gynaecol Can; 2004 May; 26(5):489-500. PubMed ID: 15151736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences.
    Lexchin J
    Health Policy; 2006 Dec; 79(2-3):214-20. PubMed ID: 16472888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilisation of hormone replacement therapy in the United Kingdom. A descriptive study using the general practice research database.
    Bromley SE; de Vries CS; Farmer RD
    BJOG; 2004 Apr; 111(4):369-76. PubMed ID: 15008775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement therapy: a comparison between gynecologists in Denmark, Norway and Sweden.
    Nilsen ST; Pedersen AT; Moen MH; Milsom I; Mattsson LA; Iversen OE; Larsen PM; Andersson K
    Maturitas; 2001 Jul; 39(1):83-90. PubMed ID: 11451625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
    Balakrishnan K; Tordoff J; Norris P; Reith D
    Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy to maintain cognitive function in women with dementia.
    Hogervorst E; Yaffe K; Richards M; Huppert F
    Cochrane Database Syst Rev; 2002; (3):CD003799. PubMed ID: 12137718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.
    Norman RJ; Flight IH; Rees MC
    Cochrane Database Syst Rev; 2000; (2):CD001018. PubMed ID: 10796730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of menopause in women with a history of endometriosis: a systematic review.
    Gemmell LC; Webster KE; Kirtley S; Vincent K; Zondervan KT; Becker CM
    Hum Reprod Update; 2017 Jul; 23(4):481-500. PubMed ID: 28498913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses.
    Banks E; Beral V; Cameron R; Hogg A; Langley N; Barnes I; Bull D; Elliman J; Harris CL
    J Epidemiol Biostat; 2001; 6(4):357-63. PubMed ID: 12036270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian menopause study-I: Understanding women's intentions to utilise hormone replacement therapy.
    Fisher WA; Sand M; Lewis W; Boroditsky R
    Maturitas; 2000 Nov; 37(1):1-14. PubMed ID: 11099868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy and symptom reporting in menopausal women: a population-based study of 35-65-year-old women in mid-Sweden.
    Bardel A; Wallander MA; Svärdsudd K
    Maturitas; 2002 Jan; 41(1):7-15. PubMed ID: 11809338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of prescribing of hormone replacement therapy in USA and Europe.
    Jolleys JV; Olesen F
    Maturitas; 1996 Feb; 23(1):47-53. PubMed ID: 8861086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone replacement therapy and cardiovascular mortality in Central-Eastern Europe.
    Acs N; Vajo Z; Miklos Z; Siklósi G; Paulin F; Szekacs B
    J Gerontol A Biol Sci Med Sci; 2000 Mar; 55(3):M160-2. PubMed ID: 10795729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.